How Medicare Might Decide To Cover Biogen's New Alzheimer's Drug
When the Food and Drug Administration last month approved a new Alzheimer’s drug made by Biogen, even though there’s not sufficient evidence the drug works, insurance companies began questioning whether they should cover the cost of the drug.
Host Robin Young talks to Rachel Cohrs, a Washington correspondent for our partners at STAT, the health and medicine publication.
This article was originally published on WBUR.org.
Copyright 2021 NPR. To see more, visit https://www.npr.org.